Bibliografía del artículo
1. Locke GR, Talley NJ, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County. Minnesota Gastroenterol 112:1448-56, 1997.
2. Van Bommel MJ, Numans ME, de Wit NJ, Stalman WA. Consultations and referrals for dyspepsia in general practice - a one year database survey. Postgrad Med J 77:514-8, 2001.
3. Díaz Rubio M, Moreno Elola-Olaso C, Rey E, Locke GR III, Rodríguez Artalejo F. Symtoms gastroesophageal reflux: prevalence, severity, duration and associated factors in a spanish population. Aliment Pharmacol Ther 19:95-105, 2004.
4. Ponce J, Vagazo O, Beltran J, Jiménez J, Zapardiel J, Calle D et al. Iberge Study Group. Prevalence of gastroesophageal reflux disease in Spain and associated factors. Aliment Pharmcol Ther 23:175-84, 2006.
5. DeVaullt KR, Castell DO. Update guidelines for the diagnosis and treatment of gastroesophageal reflux diseases. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 94:1434-42, 1999.
6. Numans ME, De Wit NJ. Reflux symptoms in general practice diagnostic evaluation of the Carlsson-Dent gastro-oesophageal reflux disease questionaire. Aliment Pharmacol Therap 17:1049-56, 2003.
7. Ellis KK, Oehlke M, Helfand M, et al. Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management? Am J Gastroenterol 92:1472-4, 1997.
8. Howden CW, Castell DO, Cohen S, et. Al. The rationale for continuos maintenance treatment of reflux oesophagitis. Arch Int Med 155:1465-71, 1995.
9. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssen J, Kahrilas PJ, et al. An evidenced-based appraisal of reflux disease management. The Genval Workshop Report. Gut 44(Suppl.2):S1-16, 1999.
10. Jones RH, Pali A, Hungin S. gastroesophageal reflux disease in primary care in Europe: clinical presentation and endoscòpic findings. Eur J Gen Pract 1:149-54, 1995.
11. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastrenterology 119(2):333-8, 2000.
12. Sampliner RE, Adenocarcinoma of the esophagus and gastric cardia: Is there progress in the face of increasing cancer incidence?. Ann Intern Med 130(1):559-63, 1999.
13. Ghillebert G, Demeyere AM, Janssens J, Vantrappen G. How well quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease? Dig Dis Sci 40:1317-24, 1995.
14. Monés J, Clave P, Mearin F. Esophageal pH monitoring: are you sure that the electrode is properly placed? Am J Gastroenterol 96:975-8, 2001.
15. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, et al. Gastroesophageal reflux disease in primary care: un international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroentero Hepatol 10:119-24, 1998.
16. Van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitotrs, H2-receptor antagonists and prokinetics for gastroesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev CD002095, 2006.
17. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 33:15-20, 1998.
18. Fass R, Ofman JJ, Gralnek IM, Johson C, Camargo E, Sampliner RE, et al. Clinical and economic assessment of the omeprazole test in patients of symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 159:2161-8, 1999.
19. Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-esophageal reflux disease. Aliment Pharmacol Ther 13:59-66, 1999.
20. Dekel R, Morse C, Fass R. The role of proton pump inhibitors in gastroesophageal reflux disease. Drugs 64:277-95, 2004.
21. Juul-Hansen P, Ryding A, Jacobsen CD, Hansen T. High-dose proton-pump inhibiors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients. Scand J Gastroenterol 36:806-10, 2001.
22. Fass R, Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is a sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-esophageal reflux disease in symptomatic patients with erosive esophagitis. Aliment Pharmacol Ther 14:389-96, 2000.
23. Johnsson F, Hatlebakk JG, Klintenberg AC, Roman J, Toth E, Stubberod A et al. One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. Scand J Gastroenterol 38:354-9, 2003.
24. Juul-Hansen P, Ryding A. Endoscopy-negative reflux disease: what is the value of proton-pump inhibitor test in everyday clinical practice? Scand J Gastroenterol 38:1200-3, 2003.
25. Madan K, Ahuja V, Gupta SD, Bal C, Kapoor A, Sharma MP. Impact of 24-h esophageal pH monitoring on the diagnosis of gastroesophageal reflux disease: defining the gold standard. J Gastroenterol Hepatol 20:30-7, 2005.
26. Numans ME, Lau J, De Wit NJ, Bonis PA. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 140:518-27, 2004.
27. Aanen MC, Numans ME, Weusten BL, Scout AJ. Diagnostic value of the reflux disease questionnaire in general practices. Digestion 74:162-8, 2006.
28. Des Varannes SB, Sacher-Huvelin S, Vavasseur F, Masliah C, Rhun ML, Aygalenq P, Bonnot-Marlier S, Lequeux Y, Galmiche JP. Rabeprazole test for the diagnosis of gastroesophageal reflux disease: Result of a study in a primary care setting. World J Gastroenterol 28:2569-73, 2006.
29. Vakil N. Test and treat or treat and test in reflux disease? Aliment Pharm Ther 17:57-60, 2003.
30. Fass R, Fennerty MB, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 115:42-9, 1998.
31. Pandak WM, Arezo S, Everett S, Jesse R, DeCosta G, CrofsT, et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry or 24-hour esophageal pH monitoring. J Clin Gastroenterol 35:307-14, 2002.
32. Xia HH, Lai KC, Lam SK, Hu WH, Wong NY, Hui WM, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopic-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 17:369-77, 2003.
33. Bautista J, Fullerton H, Briseno M, Cui H, Fass R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain - a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther 19:1123-30, 2004.
34. Dickman R, Emmons S, Cui H, Sewll J, Hernandez D, Esquivel RF, Fass R. The effect of therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled crossover trial. Aliment Pharmacol Ther 22:547-55, 2005.
35. Cremonini F, Wise J, Moayyedi P, Talley NJ. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 100:1226-32, 2005.
36. Wang WH, Huang JZ, Zheng GF, Wong WM, Lam SK, Karlberg J, Xia HH, et al. Is proton pump inhibitor testing an effective approch to diagnose gastroesophageal reflux disease in patients with non-cardiac chest pain? A metaanalysis. Arch Intern Med 165:1222-8, 2005.
37. Galli J, Scarano S, Agostino S, Quaranta N, Cammarota G, Ottaviani F. Pharyngolaringeal reflux in outpatient clinical practice: personal experience. Acta Otorhinolaryngol Ital 23:38-42, 2003.
38. DelGaudio JM, Waring JP. Empiric esomeprazole in the treatment of laryngopharyngeal reflux. Laryngoscope 113:598-601, 2003.
39. Bredenoord AJ, Tutuian R, Smout AJPM, Castell DO. Technology rewiew: esophageal impedance monitoring. Am J Gastroenterol 102:187-94, 2007.
40. Ford CN. Evaluation and management of laringopharyngeal reflux. JAMA 294:1534-40, 2005.
41. Bilgen C, Ogut F, Kesimli-Dinc H, Kirazli T, Bor S. The comparison of an empiric proton pump inhibitor trial vs 24-hour double-probe pH monitoring in laryngopharyngeal reflux. J Laryngol Otol 117:386-90, 2003.
42. Baldi F, Cappiello R, Cavoli C, Ghersi S, Torresan F, Roda E. Proton pump inhibitor treatment of patiens with gastroesophageal reflux-related chronic cough; a comparison between two different daily doses of lansoprazole. World J Gastroenterol 12:82-8, 2006.